You are leaving this website
By clicking this link, you will be leaving the NERLYNX website and will be redirected to another webpage.
Category 2A*:
Neratinib + Capecitabine27
TBCRC 022: Neratinib + capecitabine active against progressive brain metastases in patients with HER2+ brain metastases28
NALA: Neratinib + capecitabine active against symptomatic brain metastases in patients with HER2+ breast cancer26
NCCN makes no warranties of any kind whatsoever regarding its content, use, or application and disclaims any responsibility for how its content is applied or used, in any way.
*Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.27
CNS: central nervous system; HER: human epidermal growth factor receptor; mBC: metastatic breast cancer; NCCN: National Comprehensive Cancer Network.
Select IMPORTANT SAFETY INFORMATION
Hepatotoxicity: Monitor liver function tests monthly for the first 3 months of treatment, then every 3 months while on treatment and as clinically indicated. Withhold NERLYNX in patients experiencing Grade 3 liver abnormalities and permanently discontinue NERLYNX in patients experiencing Grade 4 liver abnormalities.
Please see additional IMPORTANT SAFETY INFORMATION below.
IMPORTANT SAFETY INFORMATION
NERLYNX® (neratinib) tablets, for oral use
INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:
CONTRAINDICATIONS: None
WARNINGS AND PRECAUTIONS:
ADVERSE REACTIONS: The most common adverse reactions (reported in ≥5% of patients) were:
To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
DRUG INTERACTIONS:
USE IN SPECIFIC POPULATIONS:
For Full Prescribing Information, please click here.
By clicking this link, you will be leaving the NERLYNX website and will be redirected to another webpage.
This information is intended for US healthcare professionals. Please confirm you are a healthcare professional to continue.